Core Points - The company held its 29th meeting of the 10th Board of Directors on July 7, 2025, where several key resolutions were passed, including the appointment of a new accounting firm and changes in board composition [1][2][3][4][5][6][7][8][9][10][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48][49][50][51][52][53][54][55][56][57][58][59][60][61][62][63][64][65][66][67][68][69][70][71] Group 1 - The company plans to change its accounting firm from Tianjian CPA to Lixin CPA for the 2025 financial report and internal control audit due to the expiration of the service term of the former firm [1][45][46] - The board approved the addition of a new director, Ms. Yu Xingyue, nominated by the controlling shareholder, with her term starting from the approval date by the shareholders' meeting [3][4][57][58] - The company intends to simplify its structure by canceling the indirect holding subsidiary, Hainan Taiji Pharmaceutical Import and Export Co., Ltd., to focus on its core business [5][62][63][64] Group 2 - The company will acquire 100% of the shares of Yuncheng Taiji Smart Traditional Chinese Medicine Co., Ltd. by purchasing the 90% and 10% stakes held by its subsidiaries for a nominal price of 1 yuan [6][31][32] - The company’s subsidiary, Taiji Group Chongqing Fuling Pharmaceutical Factory, will acquire 40% of Hainan Taiji Marine Pharmaceutical Co., Ltd. for 248,000 yuan, increasing its ownership from 60% to 100% [7][31][32] - The company has decided to cancel the supervisory board, transferring its responsibilities to the audit committee of the board, and will revise its articles of association accordingly [8][69][70]